An anaplastic lymphoma kinase (ALK)-positive inhibitor used for the treatment of non-small cell lung cancer (NSCLC). It less potently inhibits IGF-1R, InsR, and STK22D and IC50 value is 8, 7, and 23 nM. LDK378 is also minimally effective against a panel of other kinases. In Sep 2016, Interim adverse events and efficacy data from phase III ASCEND-4 trial in non small cell lung cancer released by Novartis. In Oct 2016, efficacy data from the phase III ASCEND-3 and ASCEND-5 trial in non small cell lung cancer was presented.https://www.bocsci.com/ceritinib-cas-1032900-25-6-item-462148.html

BOC Sciences is a brand of BOCSCI Inc. We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make best-informed decisions tailored to your evolving needs for premium chemicals. Our complete suite of CRO services spans the entire molecule development pipeline including contract research for target identification, building blocks, compound synthesis, biochemical and cellular analysis, preclinical animal tests, and clinical studies.

Products:

BOC Sciences provides a wide range of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecule and chiral compounds.

Over eight years of successful operation in the pharmaceutical industry has enabled us to possess a full-bodied array of building blocks in numerous pack sizes. BOC Sciences is constantly seeking to expand our product lines by incorporating additional potential drug like molecules.



Services:

BOC Sciences provides a wide range of services to support the pharmaceutical industry through all stages of drug discovery including Custom Synthesis of those chemicals that are not in stock, Isotope Labeling Service, Chiral Synthesis and Resolution, Bioconjugation, PEGylation services, analytical services.

Our capacity to provide pharmaceutical discovery services across the entire spectrum of the drug discovery process has assisted many of our esteemed clients in reaching their R&D goals. We are actively improving our capabilities and capacity through new expansions in BOC Sciences’s global business.



Manufacturing services:

-> Manufacture of raw materials, registered GMP starting materials and intermediates from small scale (1kg) to commercial quantities (1000 kg);
-> Production of APIs to support drug candidate selections;
-> GLP toxicology studies and clinical studies;
-> Development and optimization of environmentally friendly process;
-> Competitive quality and price comparable to commodity chemical suppliers


Our clients



As a leading provider of building blocks, synthetic intermediates, and custom synthesis, BOC Sciences is committed to supplying cost-effective products and services, which are being utilized by our customers worldwide in molecule discovery on a daily basis to promote innovations in various industries.